AD-A285 884

7	۱D)		

MIPR NO: 92MM2549

TITLE: PROSPECTIVE COLLECTION AND BANKING OF LYMPHOCYTES AND

CLINICAL DATA ON HIV INFECTED INDIVIDUAL TAKING

ANTIRETROVIRAL AGENTS

PRINCIPAL INVESTIGATOR: Richard Harris, LTC, MS

CONTRACTING ORGANIZATION: Fitzsimons Army Medical Center (HSC)

Department of Clinical Investigation

Aurora, Colorado 80045-5001

REPORT DATE: April 15, 1994

TYPE OF REPORT: Annual Report



Availability Codes

Avail and or

Special

PREPARED FOR: U.S. Army Medical Research, Development,

Acquisition and Logistics Command (Provisional),

Fort Detrick, Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;

distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

94-33832

9411 1 017

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public eporting burden for this collection of information is estimated to average. I hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarrers Services, Directorate for information Operations and Reports, 1215 Jefferson 1980 Management and Burden Reports Resources (Burden Resources College) (Management and Burden Resources Resources College) (Management and Burden Resources Resources Resources Resources (DAC) (1881) Washington (DAC) (1881) (Washington (DAC) (1881) (Washington (DAC)) (Washington (DAC)) (1881) (Washington (DAC)) (Washington (DAC)) (Washington (DAC)) (Washington (DAC)) (Washington (Washington (DAC)) (Washington (DAC)) (Washington (W

	The first transferrence of the contract and the contract		
1. AGENCY USE ONLY (Leave blank)			AND DATES COVERED
	15 April 1994	Annual Re	eport (4/1/93 - 3/31/94)
4. TITLE AND SUBTITLE			5. FUNDING NUMBERS
Prospective Collection			
and Clinical Data on		viduals	MIPR No.
Taking Antiretroviral	Agents		92MM2549
6. AUTHOR(S)			
Richard Harris, LTC,			
7. FERFORMING ORGANIZATION NAME	S) AND ADDRESS(ES)		8. PERFORMING ORGANIZATION
Fitzsimons Army Medic	al Center (HSC)		REPORY NUMBER
Department of Clinica			
Aurora, Colorado 800	45-5001		
9. SPONSORING MONITORING AGENCY	NAME(S) AND ADDRESS(ES)		10. SPONSORING - FRONTORING
U.S. Army Medical Res	AGENCY REPORT NUMBER		
Acquisition and Logis			!
Fort Detrick, Frederi	ck, Maryland 217	02-5012	}
11. SUPPLEMENTARY NOTES			
12a. DISTRIBUTION/AVAILABILITY STAT	rasan v		1 12b. DISTRIBUTION CODE
128. DISTRIBUTION / MARILABILITY STAT	LMEN I		128. DISTRIBUTION CODE
Approved for public r	elease: distribut	ion unlim	ited
			1
			ł
13. ABSTRACT (Maximum 200 words)			

FAMC has enrolled a total of 633 patients in the natural history study since its beginning. Currently, the FAMC Data Base for patient history and plasma/serum/cell collection is being integrated into the central MMCAR data base in coordination with Program area. 3. We are initiating a collaboration with Dr. Vahey, Program area 5 in coordination with Wilford Hall (Dr. Melcher). FAMC Data Base files have been sent to the Area 5 Data Manager. We are planning a coordinated evaluation of the FAMC plasma/serum/cell bank for evaluation of surrogate markers in long term HIV patients.

FAMC is cooperating with Denver's Community Programs for Clinical Research on AIDS (CPCRA) by acting as an additional enrollment site for five (5) HIV related drug studies.

FAMC is also conducting a study referred to us by the Henry M. Jackson Foundation (FAMC is not a Jackson site) for the prevention of Mycobacterium avium complex in our severely immunodeficient HIV patients. We are preparing the application to the IRC for an additional study recommended to us by HMJ.

14. SUBJECT TERMS Drug Resistance, RAD I	HIV, Agents, BL3, C	Chemotherapy,	15. NUMBER OF PAGES 16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT	18 SECURITY CLASSIFICATION OF THIS PAGE	19 SECURITY CLASSIFICATION OF ABSTRACT	30 LIMITATION OF ABSTRAC
Unclassified	Unclassified	Unclassified	Unlimited

NSN 7540 01 280 5500

Randard From 198 Rev 1 89

Primary groups for the second of Ph. 8.

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Principal Investigator's Signature Date

ANNUAL REPORT

1 MIPR No. 92MM2549

2. Report Date:

15 April 1994

3. Reporting Period from:

1 April 1993

to:

31 March 1994

4. P.L.: Richard Harris, LTC, MS

5. Phone #: (303) 361-404 /DSN 943-4042

6. Agency/ Address:

Fitzsimons Army Medical Center

HSHG-CI

Aurora, CO 80045-5001

7. Project Title:

Prospective Collection and Banking of Lymphocytes and Clinical Data on HIV Infected Individuals Taking Antiretroviral Agents. FAMC Protocol # 91/300

8. Current Staff, with percentage of effort on each project:

Richard Harris, LTC, MS

Erin Palestro, R.N.

100%

9. MIPR Expenditures to date:

\$ 79,206. Personnel

Supplies

\$257,858.

Travel

\$31,397.

Other

\$ 3,321.

Equipment

\$ 43,155.

Contracts

\$ 5,741.

Total

\$420,678.